Abstract
Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Recent Patents on Biotechnology
Title:Monoclonal Antibodies as Cancer Therapeutics
Volume: 6 Issue: 1
Author(s): Jihene Elloumi, Karim Jellali, Ikram Jemel and Sami Aifa
Affiliation:
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Abstract: Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Export Options
About this article
Cite this article as:
Elloumi Jihene, Jellali Karim, Jemel Ikram and Aifa Sami, Monoclonal Antibodies as Cancer Therapeutics, Recent Patents on Biotechnology 2012; 6 (1) . https://dx.doi.org/10.2174/187220812799789190
DOI https://dx.doi.org/10.2174/187220812799789190 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Proteasomes as Drug Targets
Current Drug Targets Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Infectious Disorders - Drug Targets Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature
Recent Patents on Anti-Cancer Drug Discovery Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS
Current Cancer Therapy Reviews Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Antifungal Drug Discovery, Six New Molecules Patented After 10 Years of Feast:Why do we Need New Patented Drugs Apart from New Strategies?
Recent Patents on Anti-Infective Drug Discovery HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry